Notably, drug candidates did not negatively impact on cell viability or cause membrane damage.<h4>Conclusion</h4>Advancing small molecules that can elevate Rab7-GTPase activity could provide opportunities to overcome cholesterol transport defects in NPC mutant cells and offer applications in other Rab7-related neurological diseases. This evidence concerns the gene NPC1 and nervous system disorder.